<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03769506</url>
  </required_header>
  <id_info>
    <org_study_id>ASP-1929-301</org_study_id>
    <nct_id>NCT03769506</nct_id>
  </id_info>
  <brief_title>Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy</brief_title>
  <official_title>A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rakuten Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rakuten Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's
      Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous
      Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of
      Therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will have an Experimental Arm and a Control Arm.

      Experimental Arm:

      Patients may receive repeated ASP-1929 PIT interventions for a period of up to 12 months
      after randomization until the patient has complete remission, progressive disease that is no
      longer amendable to study treatment, patient experiences intolerable side effects, or patient
      discontinues study treatment.

      Control Arm:

      Patients may be treated with physician's choice SOC until the patient has progressive
      disease, patient experiences intolerable side effects, or patient discontinues study
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Time to progression of disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Duration of survival between the two treatment arms</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>ASP-1929</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Physician's Choice SOC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel, cetuximab, methotrexate, paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>ASP-1929</intervention_name>
    <description>Use of ASP-1929 PIT therapy</description>
    <arm_group_label>ASP-1929</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physician's Choice SOC</intervention_name>
    <description>docetaxel, cetuximab, methotrexate, or paclitaxel</description>
    <arm_group_label>Physician's Choice SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients must have histologically confirmed locoregional persistent, recurrent or second
        primary squamous cell carcinoma of the head and neck, not amenable to curative treatment.

        Patients must have failed or progressed on or after at least 2 lines of therapy, one of
        which must be prior platinum-based chemotherapy. (Treatments such as surgery followed by
        chemotherapy and radiation, or surgery and radiation, or radiation, or surgery is
        considered one line of therapy).

        Patients must not have a history of significant reactions to cetuximab, not actively
        undergoing treatment of or have a diagnosis of an active cancer other than nonmelanoma skin
        cancer or HNSCC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace Mann</last_name>
    <role>Study Director</role>
    <affiliation>Rakuten Medical, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeannie Hou</last_name>
    <phone>650-622-7508</phone>
    <email>Jeannie.hou@rakuten-med.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzel Rodriguez</last_name>
      <phone>305-243-0124</phone>
      <email>z.rodriguez1@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Francisco Jose Civantos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Wolgast</last_name>
      <phone>313-576-8994</phone>
      <email>wolgasta@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Ammar Sukari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Gaggin</last_name>
      <phone>313-916-3731</phone>
      <email>Jgaggin1@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute, Part of Allina Health</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Erickson</last_name>
      <phone>612-863-1752</phone>
      <email>stephanie.erickson2@allina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Contreras</last_name>
      <phone>612-626-2774</phone>
      <email>contr014@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Head &amp; Neck Institute - Center for Head and Neck Oncology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Morris</last_name>
      <phone>503-215-7503</phone>
      <email>george.morris@providence.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University - Sidney Kimmel Medical College</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Poller</last_name>
      <phone>215-955-1964</phone>
      <email>Dawn.poller@jefferson.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Paul</last_name>
      <phone>215-615-0410</phone>
      <email>Ellen.Paul@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Karthik Rajasekaran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Reeves</last_name>
      <phone>713-745-1897</phone>
      <email>bereeves@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Ann Gillenwater</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olusegun Adelaja</last_name>
      <phone>804-527-4240</phone>
      <email>Oba4e@hotmail.mcc.virginia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Office of Anthanassios Argiris, MD</name>
      <address>
        <city>Maroussi</city>
        <state>Athens</state>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>info.jp@rakuten-med.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Supportive Care Center</last_name>
      <phone>04-7130-7130</phone>
      <email>chikensupport@east.ncc.go.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiminori Fujimoto</last_name>
      <phone>0942-31-7200</phone>
      <email>kradiox@med.kurume-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akihiro Homma</last_name>
      <phone>011-706-6037</phone>
      <email>ak-homma@med.hokudai.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naomi Kiyota</last_name>
      <phone>078-382-6667</phone>
      <email>nkiyota@med.kobe-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miyagi Cancer Center</name>
      <address>
        <city>Natori-shi</city>
        <state>Miyagi</state>
        <zip>981-1293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Office</last_name>
      <phone>022-384-3151</phone>
      <email>mcc-research@miyagi-pho.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama-shi</city>
        <state>Okayama</state>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Department of Otorhinolaryngology</last_name>
      <phone>81-86-223-7151</phone>
      <email>jibika@cc.okayama-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>info.jp@rakuten-med.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seiichi Yoshimoto</last_name>
      <phone>81-3-3542-2511</phone>
      <email>tsukijisupport@ml.res.ncc.go.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junichi Tomomatsu</last_name>
      <phone>03-3520-0111</phone>
      <email>junichi.tomomatsu@jfcr.or.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berta Roman Canal</last_name>
      <phone>34 93 489 43 75</phone>
      <email>broman@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Enriqueta Felip Font</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HM University Sanchinarro Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Lopez Falcon</last_name>
      <phone>34 917 567 984</phone>
      <email>llopezfalcon@hmhospitales.com</email>
    </contact>
    <investigator>
      <last_name>Lisardo Ugidos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Niaosong</city>
        <state>Kaohsiung</state>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Zhongzheng</city>
        <state>Taipei</state>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pei-Jen Lou</last_name>
      <email>pjlou@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Pei-Jen Lou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Medical Foundation</name>
      <address>
        <city>Changhua</city>
        <zip>50004</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mu-Kuan Chen</last_name>
      <email>53780@cch.org.tw</email>
    </contact>
    <investigator>
      <last_name>Mu-Kuan Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muh-Hwa Yang</last_name>
      <email>mhyang2@vghtpe.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Muh-Hwa Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai-Ping Chang</last_name>
      <email>dr.kpchang@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kai-Ping Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Greece</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>June 7, 2020</last_update_submitted>
  <last_update_submitted_qc>June 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rakuten Medical</keyword>
  <keyword>ASP-1929</keyword>
  <keyword>PIT</keyword>
  <keyword>photoimmunotherapy</keyword>
  <keyword>HNC</keyword>
  <keyword>HNSCC</keyword>
  <keyword>head and neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

